Compare Palo Alto Networks Inc (PANW) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palo Alto Networks Inc vs Tango Therapeutics Inc. — how do they compare? Palo Alto Networks Inc trades at $372.95 (market cap $324.77B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Palo Alto Networks Inc is far larger — about 86.6× Tango Therapeutics Inc.'s market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Palo Alto Networks Inc for 82 Days and Tango Therapeutics Inc. for 0 Days on average.
| PANW | TNGX | |
|---|---|---|
Market Cap | $324.77B | $3.75B |
Volume | 3,473,783 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $419.91 | $32.90 |
52-Week Low | $141.67 | $7.50 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $324.20B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palo Alto Networks (PANW) trades at $375.04, down 7.13% over the past day but remains near its 52-week high. The stock shows strong technical momentum with bullish moving averages and positive sentiment from 64 buy ratings. Recent earnings beats and robust revenue growth to $9.22B in 2025 highlight fundamental strength, though valuation ratios remain elevated with a P/E of 992.58. The company's AI-driven security platform and continuous defense services are key growth drivers, positioning it well in the cybersecurity sector.
Outlook: PANW's AI integration and platformization strategy support long-term growth, with a consensus price target of $400.05 offering ~6.7% upside. Risks include premium valuation, rising costs, and competitive pressures. Investors should weigh strong fundamentals against high multiples.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
